These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16027955)

  • 21. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
    Pongchaiyakul C; Nanagara R; Songpatanasilp T; Unnanuntana A
    J Med Econ; 2020 Jul; 23(7):776-785. PubMed ID: 32063082
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study.
    Schousboe JT; Ensrud KE; Nyman JA; Kane RL; Melton LJ
    J Clin Densitom; 2006; 9(2):133-43. PubMed ID: 16785071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy.
    Schousboe JT; Ensrud KE; Nyman JA; Kane RL; Melton LJ
    Osteoporos Int; 2005 Dec; 16(12):1883-93. PubMed ID: 16133649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.
    Johnell O; Jönsson B; Jönsson L; Black D
    Pharmacoeconomics; 2003; 21(5):305-14. PubMed ID: 12627984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
    Moriwaki K; Fukuda H
    Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
    Stevenson M; Davis S; Lloyd-Jones M; Beverley C
    Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
    Ni W; Jiang Y
    Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effective osteoporosis intervention thresholds for Hong Kong postmenopausal women.
    Kung AW; McGhee SM; Tsang SW; So J; Chau J
    Hong Kong Med J; 2015 Dec; 21 Suppl 6():13-6. PubMed ID: 26645876
    [No Abstract]   [Full Text] [Related]  

  • 30. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
    Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
    Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
    Hiligsmann M; Reginster JY
    Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
    McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
    Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China.
    Li N; Zheng B; Liu M; Zhou H; Zhao L; Cai H; Huang J
    Menopause; 2019 Aug; 26(8):906-914. PubMed ID: 30994577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis.
    Reginster J-; Bianic F; Campbell R; Martin M; Williams SA; Fitzpatrick LA
    Osteoporos Int; 2019 Jul; 30(7):1465-1473. PubMed ID: 30953114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
    Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
    Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
    Borgström F; Carlsson A; Sintonen H; Boonen S; Haentjens P; Burge R; Johnell O; Jönsson B; Kanis JA
    Osteoporos Int; 2006; 17(7):996-1007. PubMed ID: 16570118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
    Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
    J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
    Marcus R; Wang O; Satterwhite J; Mitlak B
    J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin K to prevent fractures in older women: systematic review and economic evaluation.
    Stevenson M; Lloyd-Jones M; Papaioannou D
    Health Technol Assess; 2009 Sep; 13(45):iii-xi, 1-134. PubMed ID: 19818211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.